Abstract Number: 2842 • 2017 ACR/ARHP Annual Meeting
Usefulness of Polymerase Chain Reaction for Diagnosing Whipple’S Disease in Rheumatology
Background/Purpose: Whipple's disease should be considered in patients with recurrent episodes of seronegative arthritis in the large limb, various symptoms (fever, uveitis,...) or biological abnormalities…Abstract Number: 2843 • 2017 ACR/ARHP Annual Meeting
The Relationship between Serum Urate Concentration and Incident Gout: An Individual Participant Data Analysis
Background/Purpose: Elevated serum urate concentration (hyperuricemia) is considered to be a key risk factor for developing gout. However, the relationship between serum urate and incident…Abstract Number: 2844 • 2017 ACR/ARHP Annual Meeting
Risk of Cardiovascular Events in Older Patients with Gout Initiating Febuxostat Versus Allopurinol: A Population-Based Cohort Study
Background/Purpose: Gout, a disorder of uric acid deposition, is commonly treated with xanthine oxidase inhibitors like febuxostat and allopurinol. While it is well-known that patients…Abstract Number: 2845 • 2017 ACR/ARHP Annual Meeting
Association between Serum Urate As a Surrogate Endpoint and Flares in People with Gout: An Ecological Study Based on a Systematic Review of Trials and Open Label Extensions
Background/Purpose: The primary efficacy measure in urate lowering therapy (ULT) trials is usually serum urate (SU). However, it is unknown whether the strength of the…Abstract Number: 2846 • 2017 ACR/ARHP Annual Meeting
Cause-Specific Mortality in Gout: Novel Findings of Elevated Risk of Renal-Related and Decreased Risk of Dementia-Related Death
Background/Purpose: There is recognized higher mortality among gout patients, with cardiovascular (CV) mortality having been previously reported. The present study aimed to examine cause-specific mortality…Abstract Number: 2847 • 2017 ACR/ARHP Annual Meeting
The Sons of Gout Study. Ultrasonographic Evaluation of Asymptomatic Monosodium Urate Crystal Deposition in Sons of People with Gout
Background/Purpose: Hyperuricemia and gout aggregate in families. The objectives of this study were to estimate the prevalence of asymptomatic monosodium urate (MSU) crystal deposition in…Abstract Number: 2848 • 2017 ACR/ARHP Annual Meeting
Improving Gout Outcomes: The Randomized Evaluation of an Ambulatory Care Pharmacist-Led Intervention to Optimize Urate Lowering Pathways (RAmP-Up) Study
Background/Purpose: Allopurinol is a cornerstone therapy in gout management. Despite this, allopurinol use is suboptimal as providers often fail to follow the treat-to-target paradigm…Abstract Number: 2849 • 2017 ACR/ARHP Annual Meeting
Pain and Functional Trajectories in Symptomatic Knee Osteoarthritis over a 12-Week Period of Non-Pharmacological Exercise Interventions
Background/Purpose: Exercise is the recommended treatment for knee osteoarthritis (OA). However, heterogeneous patterns in treatment response are poorly understood. Our purpose was to identify pain…Abstract Number: 2850 • 2017 ACR/ARHP Annual Meeting
Jakinibs Decrease Chronic Low Back Pain and Increase Function: A Proof of Concept Trial
Background/Purpose: Low back pain (LBP) is ubiquitous and estimated to affect 26% of Americans in any 3 month period. Why would rheumatoid arthritis patients be…Abstract Number: 2851 • 2017 ACR/ARHP Annual Meeting
General and Abdominal Obesity As Risk Factors for Late-Life Mobility Limitation Among Women with Total Knee or Hip Replacement for Osteoarthritis
Background/Purpose: The population is rapidly aging, and by 2060, more than 12 million women will be ages 85 years and older in the United States.…Abstract Number: 2852 • 2017 ACR/ARHP Annual Meeting
Widespread Pain Prior to Total Knee Replacement (TKR) Is Associated with Increased Risk of No Clinical Improvement in Pain Among Women
Background/Purpose: Up to 47% of individuals may not have clinically significant improvement following joint replacement surgery. Evidence also suggests that women are less likely to…Abstract Number: 2853 • 2017 ACR/ARHP Annual Meeting
Is Frailty Associated with Adverse Events after Total Joint Arthroplasty?
Background/Purpose: The increased volume of TJA due to the aging population requires a better understanding of the effect of physiological frailty, in addition to chronological…Abstract Number: 2854 • 2017 ACR/ARHP Annual Meeting
Optimizing Data Capture for Performance – Metrics Using Smartphone App Technology
Background/Purpose: Gait speed has been associated with many clinical outcomes (e.g. frailty, mortality, joint replacement need, etc.) relevant for rheumatologic conditions. Measuring Gait speed (stride…Abstract Number: 2855 • 2017 ACR/ARHP Annual Meeting
Subcutaneous Abatacept in Patients Aged 2–17 Years with Polyarticular Juvenile Idiopathic Arthritis and Inadequate Response to Biologic or Non-Biologic Disease-Modifying Antirheumatic Drugs: Pharmacokinetics, Effectiveness, Safety and Immunogenicity over 2 Years
Background/Purpose: IV abatacept (ABA) 10 mg/kg every 4 weeks is well tolerated and effective in reducing the signs and symptoms of polyarticular juvenile idiopathic arthritis…Abstract Number: 2856 • 2017 ACR/ARHP Annual Meeting
Evaluation of a Dosing Regimen for Tocilizumab in Patients Younger Than Two Years of Age with Systemic Juvenile Idiopathic Arthritis
Background/Purpose: Tocilizumab (TCZ) is approved for the treatment of systemic juvenile idiopathic arthritis (sJIA) based on clinical trials in patients ≥2 years of age. This…
ACR Meeting Abstracts